Management expected a 7% improvement in FEV1 in the overall population.
All they got was 3.9%.
They did get a 6.8% improvement in the biomarker group.
But, that group represent about 50% of the trial population.
Well, that mean ARRY-502 sucked in the folks without the biomarker.
We're talking about a median improvement far less that 3.9% in the non-biomarker group.
Ouch! ARRY-502 is a dud.
You may now thank me.
If the trial population is representative of the general asthma population, and 50% of that population might benefit from drug x, then I think the makers of drug x wouldn't cry too much on their way to the bank.
You do know that was just a 4-week result? MGMT expects further improvement, extrapolate that out, be conservative and make it linear, well you get 3.9*3 = 11.7 (Singulairs 9% was based on 12 weeks) Listen to the conference call then come back and bash this with facts.
In fact, all LONGS and SHORTS listen to the CC before you debate.